Earth Life Sciences Inc.
CLTS · OTC
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.81 | -0.01 | 157.16 | 2.45 |
| FCF Yield | 12,679.43% | -0.04% | -0.01% | 0.60% |
| EV / EBITDA | -357.32 | -32.87 | 0.00 | -262.09 |
| Quality | ||||
| ROIC | -0.43% | -7.36% | -0.71% | -0.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -38,317.81 | 0.01 | 0.02 | -1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 19,836,430.28% | -404.12% | -104.24% | 528.58% |
| Safety | ||||
| Net Debt / EBITDA | -16.97 | -0.83 | 0.00 | -22.28 |
| Interest Coverage | -7.92 | -69.15 | 0.00 | -2.49 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |